There are 2789 resources available
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1086P - IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study
Presenter: BIN LIAN
Session: ePoster Display
1201P - Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Presenter: Matthew Krebs
Session: ePoster Display
1202P - ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
Presenter: Didier Debieuvre
Session: ePoster Display
1076P - Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group study
Presenter: Mehmet Alpaslan Ozgun
Session: ePoster Display
1077P - Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)
Presenter: Georgina Long
Session: ePoster Display
1078P - Real-world data on patients with melanoma brain metastases and outcome related to locoregional treatment modalities and systemic therapy
Presenter: Sidsel Pedersen
Session: ePoster Display